IQVIA™ Real-World Insights Bibliography

Outpatient urticaria diagnosis codes have limited predictive value for same-day influenza vaccine adverse event detection
Author(s): Moore KM, Duddy A, Lee GM, Velentgas P, Burwen DR, Platt R, Brown JS
Affiliations(s): 
Publication(s):  J Clin Epidemiol. 2010 Apr;63(4):407-11
Document Type(s): Article,
Countries: 
C:
Y:
Immunology and Vaccination,
2010
  L:
A:
English
RWLPR (Real-World Late Phase Research-quintiles,
  Add to report
 
 
The cost-effectiveness of 13-valent pneumococcal conjugate vaccine (pcv13) compared to 7-valent pneumococcal conjugate vaccine (pcv7) for childhood vaccination in Germany.
Author(s): Patel, R1, Kuchenbecker, U2, Bowrin, K1, Lloyd, A1
Affiliations(s): 1 IMS Health, London, UK 2 Wyeth Pharmaceuticals, Muenster, Germany
Publication(s):  27th Annual Meeting of the European Society for Paediatric Infectious Diseases Brussels, Belgium, June 9-13, 2009
Document Type(s): Poster,
Countries: Germany,
C:
Y:
Immunology and Vaccination,
2009
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Paediatric vaccination programmes against HPV: an individual-based simulation model
Author(s): Thompson, W1
Affiliations(s): 1 IMS Health, London, UK
Publication(s):  27th Annual Meeting of the European Society for Paediatric Infectious Diseases Brussels, Belgium, June 9-13, 2009
Document Type(s): Poster,
Countries: UK,
C:
Y:
Immunology and Vaccination,
2009
  L:
A:
English
Epidemiological study,
  Add to report
 
 
The Cost-Effectiveness of the new Pneumococcal 13-Valent Conjugate Vaccine (Pcv13) for childhood and adult vaccination in the UK
Author(s): Patel R1, Stoykova B2, Lloyd AC1, Willingham J2, Hollingsworth R2
Affiliations(s): 1IMS Health, London, UK, 2Wyeth, Maidenhead, Berkshire, UK
Publication(s):  ISPOR 12th Annual European Congress, Paris, France, 24-27 October 2009
Document Type(s): Poster,
Countries: UK,
C:
Y:
Immunology and Vaccination,
2009
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
A Comparison of the cost effectiveness of the 13-Valent (Pcv13) and 10-Valent Pneumococcal Conjugate Vaccines in the UK
Author(s): Patel R1, Stoykova B2, Lloyd AC1, Willingham J2, Hollingsworth R2
Affiliations(s): 1IMS Health, London, UK, 2Wyeth, Maidenhead, Berkshire, UK
Publication(s):  ISPOR Paris, France, 24-27, October 2009
Document Type(s): Poster,
Countries: UK,
C:
Y:
Immunology and Vaccination,
2009
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis.
Author(s): Pelletier EM1, Ogale S2, Yu E2, Brunetta P2, Garg J2
Affiliations(s): 1IMS Health, Watertown, MA, USA, 2Genentech Inc., South San Francisco, CA, USA
Publication(s):  Clinical Therapeutics, 2009, 31(11): 2653-2664
Document Type(s): Manuscript in preparation,
Countries: USA,
C:
Y:
Immunology and Vaccination,
2009
  L:
A:
English
Cost analysis,
  Add to report
 
 
An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice
Author(s): Poole CD, Conway P & Currie CJ
Affiliations(s): Pharmatelligence, Medicentre, University Hospital of Wales
Publication(s):  Rheumatology (Oxford). 2009 Jan;48(1):78-82. doi: 10.1093/rheumatology/ken415.
Document Type(s): Abstract, Article,
Countries: UK,
Click here for the abstract
C:
Y:
Immunology and Vaccination,
2009
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Implementation of rapid cycle analysis for detection of potential excess risk of adverse events following influenza vaccination: A policy maker?s guide
Author(s): Brown JS, Velentgas P, Kuldorff M, Moore KM, Duddy A, Platt R
Affiliations(s): 
Publication(s):  Prepared for Center for Biologics Evaluation and Research, Food and Drug Administration. 2009
Document Type(s): 
Countries: 
C:
Y:
Immunology and Vaccination,
2009
  L:
A:
English
RWLPR (Real-World Late Phase Research-quintiles,
  Add to report
 
 
Implementation of rapid cycle analysis for detection of potential excess risk of adverse events following influenza vaccination: A policy maker?s guide
Author(s): Brown JS, Velentgas P, Kuldorff M, Moore KM, Duddy A, Platt R
Affiliations(s): 
Publication(s):  Prepared for Center for Biologics Evaluation and Research, Food and Drug Administration. 2009
Document Type(s): 
Countries: 
C:
Y:
Immunology and Vaccination,
2009
  L:
A:
English
RWLPR (Real-World Late Phase Research-quintiles,
  Add to report
 
 
Estudio del impacto económico de la gripe en el medio laboral [A study of the economic impact of influenza on the labour environment]
Author(s): Badia Llach X1, Roset Gamisans M1, de Agustín de Oro T2, Álvarez Sanz C2, García Pulgar M2
Affiliations(s): 1 Health Economics and Outcomes Research. IMS Health. Barcelona. 2 Roche Farma, S.A. Madrid
Publication(s):  Medicina del Trabajo 2008;17(1):21-29
Document Type(s): Article,
Countries: Spain,
C:
Y:
Immunology and Vaccination,
2008
  L:
A:
Spanish
Observational study,
  Add to report
 
 
First Page Previous Page  6 of 7 Next Page Last Page